跳至主要内容
临床试验/NCT05313828
NCT05313828Unknown不适用

Effect of Various Treatment Modalities on Dendritic Vial Ulcer

Sohag University1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2022年3月18日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
入组人数
40
试验地点
1
主要终点
healing of the epithelium

研究概览

简要总结

Eye infection is a prevalent problem in primary care and remains a crucial healthcare concern. According to the American Academy of Ophthalmology (AAO), herpes simplex virus (HSV) keratitis (HSK) is the leading cause of infectious blindness worldwide . HSK is defined as a corneal inflammatory condition caused by the HSV infection . The global incidence of herpetic keratitis is estimated at 1.5 million per year, resulting in 40,000 new cases of severe visual impairment associated with corneal scarring and opacification . HSV type I (HSV-1) is by far the most predominant causative pathogen of eye infections]. HSV-1 is also known for causing orolabial herpes, HSV folliculitis, herpes gladiatorum, herpetic whitlow, and eczema herpeticum . HSV can be transferred to the eye by touching an active lesion and then the eye. The National Health and Nutrition Evaluation revealed a seroprevalence of HSV-1 in 53.9% of 14-49 year olds, and 90% of adults 50 years or older , indicating that the majority of the population has been exposed to this virus thus are at risk of developing HSK.

In this study we evaluate the efficacy of different treatment modalities on viral keratitis HSK.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • patients with epithelial viral ulcers

排除标准

  • patients with stromal keratitis patients with corneal opacity

研究组 & 干预措施

group 1'

patients with viral ulcers will receive antiviral medication with antibiotics

干预措施: Acyclovir (Drug)

group 1'

patients with viral ulcers will receive antiviral medication with antibiotics

干预措施: Tobramycin (Drug)

group 2

patients with viral ulcers will receive antiviral medication, tear substitutes with antibiotics

干预措施: Acyclovir (Drug)

group 2

patients with viral ulcers will receive antiviral medication, tear substitutes with antibiotics

干预措施: Tobramycin (Drug)

group 2

patients with viral ulcers will receive antiviral medication, tear substitutes with antibiotics

干预措施: Sodium Hyaluronate (Drug)

group 3

patients with viral ulcers will receive antiviral medication, weak steroids(at the same time) with antibiotics

干预措施: Acyclovir (Drug)

group 3

patients with viral ulcers will receive antiviral medication, weak steroids(at the same time) with antibiotics

干预措施: Tobramycin (Drug)

group 3

patients with viral ulcers will receive antiviral medication, weak steroids(at the same time) with antibiotics

干预措施: Fluorometholone (Drug)

group 4

patients with viral ulcers will receive antiviral medication with antibiotics followed by weak steroid after epithelial healing

干预措施: Acyclovir (Drug)

group 4

patients with viral ulcers will receive antiviral medication with antibiotics followed by weak steroid after epithelial healing

干预措施: Tobramycin (Drug)

group 4

patients with viral ulcers will receive antiviral medication with antibiotics followed by weak steroid after epithelial healing

干预措施: Fluorometholone (Drug)

结局指标

主要结局

healing of the epithelium

时间窗: 10 days follow up

the epithelial healing assessed with flourescin stain and measured by slit lamp scale in millimetres and compared with pre treatment epithelial defect

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Hany Mahmoud,MD

principal investigator

Sohag University

研究点 (1)

Loading locations...

相似试验